Redhill Biopharma
RDHL
30 hedge funds and large institutions have $40.7M invested in Redhill Biopharma in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
89% more capital invested
Capital invested by funds: $21.5M → $40.7M (+$19.2M)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 29 → 30 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.41M |
| 2 |
KC
Kepos Capital
New York
|
+$1.39M |
| 3 |
II
Ibex Investors
Denver,
Colorado
|
+$312K |
| 4 |
JP Morgan Chase
New York
|
+$293K |
| 5 |
Millennium Management
New York
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$738K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$145K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$130K |
| 4 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$96K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$82.7K |
RDHL Hedge Fund Activity: Q2 2018 in Review
30 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q2 2018, worth a combined $40.7M — up 89% from $21.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new RDHL positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $2.41M. The largest seller was Altshuler Shaham, cutting an estimated $738K.
- 30 institutional investors held Redhill Biopharma (RDHL) as of Q2 2018, up from 29 in Q1 2018.
- Funds reported $40.7M of Redhill Biopharma stock for Q2 2018, up 89% quarter-over-quarter.
- 5 funds opened new Redhill Biopharma positions in Q2 2018 and 4 closed out, a net change of +1 holder.
- The largest Redhill Biopharma buyer in Q2 2018 was 683 Capital Management, an estimated $2.41M added.
- The largest Redhill Biopharma seller in Q2 2018 was Altshuler Shaham, an estimated $738K sold.
Based on aggregated 13F filings for Q2 2018.